KalVista sees a win in PhII for the rare ge­net­ic dis­or­der HAE as it con­tin­ues to chart a post-Mer­ck course

Rough­ly a year af­ter Mer­ck walked away from a part­ner­ship with KalVista fol­low­ing a flop in di­a­bet­ic mac­u­lar ede­ma, the biotech is back with da­ta from an­oth­er pro­gram it hopes can put it back on the map.

KalVista re­port­ed topline Phase II re­sults for its lead can­di­date KVD900, an oral ther­a­py meant to stem the ef­fects of swelling at­tacks caused by the rare ge­net­ic dis­or­der hered­i­tary an­gioede­ma. In the 53-pa­tient tri­al, the pro­gram hit sta­tis­ti­cal sig­nif­i­cance across all end­points, re­duc­ing the need for in­di­vid­u­als to use fur­ther treat­ment in sub­se­quent at­tacks and al­le­vi­at­ing symp­toms more quick­ly than place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER